|
1 pahu (10 Vials)
| Ka nui: | |
|---|---|
▎ Bpc 157 Huina
Puna: PubChem |
Kaʻina: GEPPPGKPADDAGLV Hui Molekala: C 62H 98N 16O22 Kaumaha Molekala: 1419.5g/mol Helu CAS: 137525-51-0 PubChem CID: 9941957 Nā huaʻōlelo like: Bepecin |
▎ Bpc 157 Imi
He aha ke kumu noiʻi o Bpc 157?
ʻO ka Bpc 157 he peptide i haku ʻia me 15 amino acids a he ʻāpana ia o ke kaʻina o ka pūhui pale kino (Bpc) i ʻike ʻia a hoʻokaʻawale ʻia mai ka wai ʻōpū o ke kanaka. Ma lalo iho nei ka ʻimi noiʻi e pili ana i ka Bpc 157:
ʻO ke Axis Brain-Gut a me Bpc 157:
Hoʻopili ka pilina o ka lolo-gut i nā mea ulu peptidergic. I waena o lākou, ʻo ka gastric pentadecapeptide Bpc 157 he lāʻau anti-ulcer peptidergic i palekana a maikaʻi hoʻi i nā hoʻāʻo ʻana o ka maʻi ʻōpū a ke hoʻāʻo nei i nā hoʻokolohua no ka sclerosis lehulehu. Aia maoli ia i loko o ka wai ʻōpū o ke kanaka [1] . Hiki i ka Bpc 157 ke hana ma ke ʻano he mea hoʻoponopono hou no ka pale ʻana o Robert cell, e komo ana i ka mālama ʻana i ka pono o ka mucosa gastrointestinal me ka ʻole o nā hopena ʻawaʻawa.
Ua loaʻa iā ia ka kūleʻa i ka mālama ʻana i nā maʻi gastrointestinal, periodontitis, ate a me nā maʻi pancreatic, a me ka ho'ōla ʻana i nā ʻiʻo like ʻole a me nā ʻeha. Hoʻoulu pū ia i nā alahele Egr-1, NAB2, FAK-paxillin, a me JAK-2 [1] .Ke hoʻohana ʻia ʻo Bpc 157 i ka peripheral, ʻike mua ʻia nā hopena koʻikoʻi e pili ana, ʻoi aku ka nui o ka hoʻololi ʻana i ka hoʻokuʻu ʻana o serotonin i kekahi mau wahi o ka lolo (ka nui o ka nigrostriatal region). Hoʻoponopono ʻo Bpc 157 i nā ʻōnaehana serotonergic a me dopaminergic, loaʻa ka hopena maikaʻi i nā ʻano maʻi ʻano like ʻole e kū mai ana ma muli o ka hoʻoulu ʻana / pōʻino o ka ʻōnaehana neurotransmitter.
Eia kekahi, loaʻa i ka Bpc 157 nā hopena neuroprotective, e like me ka pale ʻana i nā neurons somatosensory, ka hoʻoikaika ʻana i ke aʻalolo peripheral, ke kūʻē i ke kaʻina holomua ma hope o ka ʻeha o ka lolo traumatic, ka pale ʻana i ka axonal a me ka necrosis neuronal, demyelination, a me ka hoʻokumu ʻana o ka cyst i nā ʻiole me ka hoʻopā ʻana i ka spinal cord i hui pū ʻia me ka caudal caudal function . .
ʻO ke kuleana i ka mālama ʻana i ka maʻi maʻi maʻi a me ka pale kino:
He mea koʻikoʻi ka Bpc 157 ma ke ʻano he mea uʻi no ka pale ʻana o ka ʻōpū o ka ʻōpū o Robert/adaptive cell protection a me ka pale o ke kino, a me kahi mea uʻi hou no ka pane koʻikoʻi o Selye. Mālama ʻo Bpc 157 i nā ʻōpū o ka ʻōpū a mālama i ka pono o ka ʻōpū mai nā mea ʻino like ʻole.
Hiki iā ia ke pale i nā hopena maikaʻi ʻole o ka waiʻona a me nā lāʻau anti-inflammatory non-steroidal ma ka epithelium ʻōpū a me nā epithelia ʻē aʻe (e like me ka ʻili, ate, pancreas, naʻau, a me ka lolo), a loaʻa iā ia nā noi i ka hoʻōla ʻana i nā ʻeha. Eia kekahi, hiki i ka Bpc 157 ke pale aku i ka pōʻino endothelial o ka ʻōpū, pale i nā endothelia vascular ʻē aʻe, loaʻa ka hopena maikaʻi i nā kīʻaha koko, kūkulu hou i ka pono o ke kahe koko, a me ka pale ʻana i ka cachexia tumo, ka hoʻopau ʻana i ka ʻiʻo, a me ka hoʻonui ʻana i nā cytokines pro-inflammatory / cachectic [2] .
ʻO ke kuleana Therapeutic i ka Vascular Occlusion:
Ma ke aʻo ʻana o ke aʻa mesenteric kiʻekiʻe a me ka hoʻopaʻa ʻana o nā vein i nā ʻiole, hiki i ka Bpc 157 ke hoʻoikaika wikiwiki i nā ala collateral, me ka mesenteric vein-inferior anterior pancreaticoduodenal vein-superior anterior pancreaticoduodenal vein-pyloric vein-portal vein vein alahele i ke ala waena a me nā ala ʻē aʻe. mesenteric vein haʻahaʻa, a me ke aʻaʻa pancreaticoduodenal mua a me ke aʻa mesenteric inferior.
Hiki i ka Bpc 157 ke pale aku i ka sagittal sinus, portal vein, a me inferior vena cava hypertension, aortic hypotension, progressive venous and arterial thrombosis ma ka ʻaoʻao a me ke kikowaena wahi, e hoʻēmi i nā ʻeha o nā mea he nui, nā ʻeha i loko o ka puʻuwai, nā māmā, ke akepaʻa, nā puʻupaʻa, ka ʻōpū o ka ʻōpū, ʻoi aku ka pilikia o ka lolo, a me ka ʻiʻo ..
ʻO ke kuleana i ka Budd-Chiari Syndrome: Ma ke aʻo ʻana i ke kumu hoʻohālike Budd-Chiari syndrome (ka hoʻopili ʻana o ka suprahepatic vena cava) i nā ʻiole, hiki i ka Bpc 157 ke hana wikiwiki i nā ala bypass o ka vena cava-azygos vein haʻahaʻa (hemiazygos vein) -superior vena cava a me ka portacaval portal. aortic hypotension, a ho'ēmi i ka thrombosis, electrocardiogram maʻi, a me nā lesions i loko o ke ake a me ka gastrointestinal tract. I ka wā o ka ligation, e mau ana nā pae o ka nitric oxide a me ka malondialdehyde i loko o ke ake i loko o ka pae waiwai olakino maʻamau, a ua hoʻemi nui ʻia ka piʻi ʻana o nā enzyme serum [4].
ʻO ke kuleana Therapeutic hiki i ka COVID-19:
Manaʻo ʻia ʻo COVID-19 he maʻi thrombotic a me ka maʻi vascular e kuhikuhi nui ana i nā cell endothelial systemic, hiki ke kumu i ka dysfunction vascular central, e alakaʻi ana i nā hoʻopiʻi a me ka hāʻule ʻole o ka multi-organ. ʻO ka Bpc 157 kahi peptide i loaʻa nā hopena anti-inflammatory, cytoprotective, a me endothelial i nā ʻōnaehana o nā ʻano like ʻole. Hiki iā ia ke hoʻoulu i ka endothelial nitric oxide synthase, e pili ana i ka hoʻokuʻu ʻana o ka nitric oxide, ka hoʻoponopono ʻana i ka ʻiʻo, a me nā waiwai hoʻoponopono vascular, hoʻomaikaʻi i ka pono o ka vascular a me ka pane ʻana i ka pale ʻana, hoʻemi i ke kūlana pro-inflammatory, a hoʻemi i ka paʻakikī o ka maʻi. No laila, he mea koʻikoʻi ke kūkākūkā ʻana i kona hiki ke ʻano he ʻano pale a me ke ʻano lapaʻau hou [5] (Deek SA, 2022).
He aha ke ʻano kikoʻī o ka hana a Bpc 157 i ka axis lolo-gut?
ʻO ka axis brain-gut kahi ʻōnaehana kamaʻilio paʻakikī ʻelua e pili ana i ka pilina ma waena o ka ʻōnaehana nerve a me ka ʻōpū o ka ʻōpū, a he kuleana koʻikoʻi ʻo Bpc 157 i loko o ia mea, ʻo ka mea nui ma ʻekolu mau ʻano: ʻO ka mea mua, ma ke ʻano he cytoprotective mediator, hiki i ka Bpc 157 ke komo i ka mālama pono ʻana o ka mucosa gastrointestinal. Ma ke ʻano he mediator hou o ka pale cell Robert me ka ʻole o nā hopena ʻawaʻawa, mālama ia i ka hana physiological maʻamau o ka gastrointestinal tract ma o ka pale ʻana i nā cell gastrointestinal, a laila e hoʻopili ai i ke koena o ka axis brain-gut. ʻO ka lua, hoʻoponopono ia i ka ʻōnaehana neurotransmitter. Hiki i ka Bpc 157 ke hoʻoponopono i nā ʻōnaehana serotonergic a me dopaminergic. Ke lawelawe ʻia ʻo Bpc 157 ma ke ʻano holoʻokoʻa, e loli ka hoʻokuʻu ʻana o ke serotonin ma nā wahi o ka lolo (ka nui o ka ʻāina nigrostriatal), e hana ana i nā hopena koʻikoʻi. Eia kekahi, hiki iā ia ke hoʻopōmaikaʻi i nā ʻano maʻi kūlohelohe e kū mai ma muli o ka hoʻoulu ʻana / pōʻino o ka ʻōnaehana neurotransmitter. No ka laʻana, hoʻoponopono ia i nā ʻōnaehana serotonergic a me dopaminergic e hoʻomaikaʻi i nā pilikia kūlohelohe i hana ʻia e nā ʻōnaehana neurotransmitter abnormal. ʻO ke kolu, loaʻa iā ia nā hopena neuroprotective. Hiki i ka Bpc 157 ke pale i nā neurons somatosensory, hoʻoikaika i ke ola neuron a me ka hoʻihoʻi ʻana i ka hana i ka wā o ka hōʻeha ʻana o ke aʻalolo, hoʻoikaika i ka hoʻoulu hou ʻana o ke aʻalolo peripheral, a hoʻihoʻi i ka hana hoʻokele nerve, e hōʻemi ana i ka hōʻeha lolo. No ka laʻana, i ka hihia o ka spinal cord compression i nā ʻiole i hele pū ʻia me ka caudal paralysis, axonal and neuronal necrosis, demyelination, a me cyst formation, hiki i ka Bpc 157 ke hoʻopakele i ka hana caudal a hōʻemi i ka pōʻino o nā kino e like me ka ʻōnaehana nerve a me ka ʻōpū o ka ʻōpū i hoʻokumu ʻia e ka overdose a i ʻole encephalopathy, pale i nā hana maʻamau o ke kino [1].
He aha ke ʻano kikoʻī o Bpc 157 i ka mālama ʻana i nā maʻi maʻi o ke kikowaena?
Ua hōʻike ʻo Bpc 157 i nā ʻano hana like ʻole i ka mālama ʻana i nā maʻi maʻi o ke kikowaena. Ma ke kŘkohu o ka cerebral ischemic stroke, Bpc 157 e pale pono i ka hahau i hookomoia e ka bilateral common carotid artery clamping by protecting neurons and supporting specific gene expression. Hiki iā ia ke hoʻoponopono i ka pōʻino mau i nā neurons lolo i nā ʻiole, ʻoiai e hoʻomaikaʻi ana i ka hoʻomanaʻo pilikia, ka moto, a me ka hiki ke hoʻonohonoho. Loaʻa iā ia kahi hopena pale pololei i ka pōʻino neuronal i hoʻokumu ʻia e ka ischemic stroke a kākoʻo pū i ka hōʻike ʻana o nā genes kikoʻī i ka ʻiʻo hippocampal. Hiki iā ia ke hoʻoikaika i ke ola a me ka hoʻihoʻi hou ʻana o nā neurons ma o ka hoʻoponopono ʻana i ka ʻōlelo o nā genes kikoʻī [6] .
Nā hiʻohiʻona o nā hana hoʻokele holomua no ka lawe ʻana i ka BPC 157; ʻO nā ala āpau, kūloko a me ka ʻōnaehana, ua hōʻike ʻia he hopena hoʻōla maikaʻi
Puna:PubMed [7]
No ka schizophrenia, hoʻoponopono ʻo Bpc 157 i ka pilina ma waena o ka ʻōnaehana nitric oxide a me ka ʻōnaehana dopamine a pale i nā ʻano like ʻole o ka ʻōnaehana dopamine, a laila e hoʻomaikaʻi ai i nā hōʻailona o ka schizophrenia. Hiki iā ia ke hoʻoponopono i ka pilina paʻakikī ma waena o ka ʻōnaehana nitric oxide a me amphetamine, apomorphine, MK-801, a me ka hoʻokele methylphenidate mau, e hōʻike ana e hiki ke hoʻomaikaʻi i nā hōʻailona o ka schizophrenia ma ka hoʻoponopono ʻana i nā hana o ka ʻōnaehana nitric oxide a me ka ʻōnaehana dopamine. Hiki iā ia ke pale aku i nā ʻano like ʻole o ka ʻōnaehana dopamine, e like me ka dopamine receptor blockade, ka hoʻomohala ʻana o ka hypersensitivity receptor, ka hoʻoulu ʻana o ka mea i loaʻa, ka hoʻokuʻu nui ʻana, ka pōʻino nigrostriatal, a me ka depletion vesicular, a me nā mea ʻē aʻe . .
Eia kekahi, ma ke ʻano he ʻano hou o ka cytoprotective mediator, hoʻoponopono ʻo Bpc 157 i nā ʻōnaehana serotonergic a me dopaminergic, he hopena maikaʻi i nā maʻi kūlohelohe, a ma o kāna hopena neuroprotective, pale i nā neurons somatosensory, hoʻoikaika i ka hoʻoulu hou ʻana o ke aʻalolo peripheral, kūʻē i ka holomua o ka ʻeha o ka lolo traumatic, a hoʻihoʻi i ka hana caudal. Hiki iā ia ke hana ma ke ʻano he ʻano hou o ka cytoprotective mediator, komo i ka mālama ʻana i ka pono o ka mucosa gastrointestinal, a loaʻa i kahi hopena therapeutic indirect i nā maʻi ʻōnaehana kikowaena. Hiki iā ia ke hoʻoponopono i nā ʻōnaehana serotonergic a me dopaminergic, loaʻa ka hopena maikaʻi i nā ʻano maʻi ʻano like ʻole e kū mai ana ma muli o ka hoʻoulu ʻana / pōʻino o ka ʻōnaehana neurotransmitter, a i ka manawa like me nā hopena neuroprotective, e like me ka pale ʻana i nā neurons somatosensory, e hoʻoikaika ana i ka peripheral nerve regeneration, counteracting the progression of traumatic nex brain injury. ka hoʻokumu ʻana o ka cyst i nā ʻiole me ka hoʻopaʻa ʻana i ke kuamoʻo, a me ka hoʻihoʻi ʻana i ka hana caudal [1] .
He aha nā haʻawina e pili ana i ka Bpc 157?
Ma ke ʻano he lapaʻau kūpono no COVID-19:
I ka hopena o ka makahiki 2019, ua hoʻomaka ka maʻi coronavirus 2019 (COVID-19) i kahi maʻi maʻi nui ma ka honua holoʻokoʻa. Hōʻike ka noiʻi ʻo COVID-19 ka nui o ka maʻi thrombotic a me ka maʻi vascular e kuhikuhi ana i nā cell endothelial systemic, hiki ke alakaʻi i ka hoʻopau ʻana i ka hana vascular central [5] . Hiki i nā poʻe maʻi me COVID-19 ke hoʻomohala i nā hemahema he nui e like me ka acute respiratory distress syndrome, ka hoʻopiʻi cardiovascular, ka ʻeha o ka ate, a me ka ʻeha nerve. Ma muli o ka ʻikepili hoʻohālike holoholona, ua kūkākūkā nā mea noiʻi i ke kuleana o Bpc 157 ma ke ʻano he lāʻau lapaʻau no ka hoʻomaikaʻi ʻana i ka hoʻokele olakino o COVID-19. ʻO ka Bpc 157 kahi peptide e hōʻike ana i nā hopena anti-inflammatory, cytoprotective, a me endothelial i nā ʻōnaehana o nā ʻano like ʻole. Hoʻoulu ka Bpc 157 i ka endothelial nitric oxide synthase (eNOS), e pili ana i ka hoʻokuʻu ʻana o ka nitric oxide (NO), ka hoʻoponopono ʻana i ka ʻiʻo, a me nā waiwai hoʻoponopono vascular, a hiki ke hoʻomaikaʻi i ka pono o ka vascular a me ka pane ʻana i ka pale, hoʻemi i ka mokuʻāina pro-inflammatory, a hoʻemi i ka paʻakikī o ka maʻi. No laila, he mea koʻikoʻi ke kūkākūkā ʻana i kona hiki ke ʻano he ʻano pale a me ka adjuvant.
ʻO ka hoʻomaʻamaʻa ʻana i ka hoʻōla ʻana o ka ʻiʻo palupalu musculoskeletal:
Ua mālamaʻia kahi loiloi e pili ana i ka hana a Bpc 157 i ka mālamaʻana i nāʻehaʻeha palupalu [7] . I kēia manawa, ua hōʻikeʻia nā hoʻokolohua a pau e aʻo ana i ka Bpc 157 no nāʻanoʻeha likeʻole (me nāʻeha traumatic a me ka pūnaewele a me nāʻanoʻehaʻeha palupalu), loaʻa ka Bpc 157 i ka hopena maikaʻi a me ka wikiwiki. Eia naʻe, a hiki i kēia lā, ua mālama ʻia ka hapa nui o nā haʻawina ma nā hiʻohiʻona rodent liʻiliʻi, a ʻaʻole i hōʻoia ʻia ka pono o Bpc 157 i nā kānaka. Eia nō naʻe, ʻike maopopo ʻia ʻo Bpc 157 e lilo i ʻano lapaʻau no ka mālama conservative o nā ʻiʻo palupalu haʻahaʻa a me ka liʻiliʻi liʻiliʻi (e like me nā tendons a me nā ligaments) ʻeha a i ʻole he adjuvant no ka hoʻihoʻi ʻana ma hope o ka hoʻomohala hou ʻana. Eia kekahi, ke hōʻike nei ka hōʻailona hōʻeha i ka ʻiʻo skeletal ʻaʻole i loaʻa i ka Bpc 157 ka hopena maikaʻi wale nō i nā ʻeha i hana ʻia e ka trauma pololei akā i nā ʻeha pūnaewele pū kekahi me ka hyperkalemia a me ka hypermagnesemia.
Hoʻomaikaʻi i ka hana kaʻa ma hope o ka hōʻeha ʻana i ka spinal Cord:
Ua hoʻohana ka poʻe noiʻi i kahi ʻano ʻiole i hoʻolālā maikaʻi ʻia e hōʻike i ka hiki i ka pentadecapeptide gastric stable Bpc 157 ke hoʻomaikaʻi i ka ʻeha spinal cord [8] . Ua hōʻike nā haʻawina mua e hiki i ka Bpc 157 ke pale aku i nā hopena o ka peripheral (sciatic nerve) nerve transection / anastomosis a hoʻomaikaʻi i ka hoʻōla ʻana o ke aʻalolo, ka ʻeha lolo, a me nā encephalopathies like ʻole. Ua hoʻohana ʻia ʻo Bpc 157 ma ke ʻano he anti-ulcer peptide i nā hoʻāʻo ʻana o ka maʻi ʻōpū a me nā hoʻāʻo sclerosis lehulehu. Ma hoʻokahi haʻawina, ua loaʻa i nā ʻiole hoʻokahi hoʻokahi intraperitoneal injection o Bpc 157 (200 a i ʻole 2μg / kg) a i ʻole saline maʻamau (5ml / kg) ma hope o ka hōʻeha ʻana i ke kuamoʻo. ʻO nā ʻiole āpau i hōʻeha i hōʻike i ka hoʻomaikaʻi mau ʻana ma hope o ka mālama ʻana i ka Bpc 157, me ka ʻoi aku ka maikaʻi o ka hana kaʻa kaʻa huelo maʻi a ʻaʻohe ʻano hana ʻoki kino; ua hoʻopau ʻia ka pilikia spasm ma ka lā 15; ma lalo o ka microscope (hoʻomaka mai ka 7th lā), nā vacuoles a me ka poho axonal i loko o ke keʻokeʻo mea, edema i loko o ka hina mea, a me ka nalowale o ka motor neurons i Bpc 157 iole, a me ka emi ana o ka nui myelinated axons i loko o ka iole caudal aʻalolo, ua nui counteracted. Ua hōʻike ʻia ka hoʻopaʻa ʻana o Electromyogram i ka emi nui o nā mea hiki i nā ʻāpana kaʻa ma nā ʻiʻo huelo. Eia kekahi, ua hana nā mea noiʻi i kahi hoʻokolohua ʻē aʻe. Hoʻohana ʻia ʻo Bpc 157 i nā lā 4 ma hope o ka hōʻeha ʻana i ke kuamoʻo, a ua hāʻawi ʻia ʻo Bpc 157 (10μg / kg, 0.16μg / mL, 12ml / rat / lā) ma o ka wai inu no nā wiki 4, ʻoiai ʻo ka hui mana i loaʻa i ka wai inu wale nō. Ua hōʻike nā hopena i nā ʻiole i mālama ʻia me ka Bpc 157 i hōʻike i ka hoʻomaikaʻi maikaʻi ʻana a hoʻomau i ke ola a hiki i ka hoʻōla piha ʻana.
Ke kū'ē i ka pilikia o ke kuamoʻo:
No ka hoʻouluʻana i ka spinal instability i nāʻiole, ua nānā nā mea noiʻi i ka bilateral facetectomy a uaʻimi i nā pono therapeutic kūpono o ka gastric pentadecapeptide Bpc 157 paʻa i ka wai inu [9] . I loko o kēia haʻawina, ua loaʻa i nā ʻiole piha piha L3-L4 facetectomy, a ma hope o ka hana ʻana, hāʻawi ʻia lākou i ka Bpc 157 (10ng/kg, 0.16ng/mL, 12ml/rat/lā) a i ʻole ka wai inu wale nō. Ua hana ʻia nā loiloi radiological i ka pule 1 a me ka wiki 8. Ua hōʻike ʻia nā hopena i ka pule 1, ʻaʻohe deformity maopopo i ʻike ʻia i nā ʻiole o ka pūʻulu mana a me ka hui Bpc 157 i kēlā me kēia mokulele, ʻaʻole i hoʻopilikia ʻia ka intervertebral disc space, ʻo ka neural foramen ma ke kiʻekiʻe ʻokiʻoki ua hoʻonui iki ʻia, a ʻoi aku ka kiʻekiʻe o nā ʻiole o ka hui Bpc 157. I ka pule 8, ʻaʻole i ʻike ʻia kahi deformity i nā ʻiole o nā hui ʻelua i kēlā me kēia mokulele, ʻaʻole i hoʻopilikia ʻia ka intervertebral disc space, ua hoʻonui iki ʻia ka neural foramen ma ke kiʻekiʻe o ke kaʻina hana, ua ʻoi aku ka nui o nā ʻiole o ka hui Bpc 157, a ua nele ka nui o ka hoʻokumu ʻana o ka callus i kahi hiʻohiʻona i ʻike ʻia i ka pūʻulu mana. Eia kekahi, ua hōʻike nā ʻiole o ka hui hoʻomalu i ka pōʻino o ka kaʻa ma hope koke o ka hoʻokomo ʻana i ka ʻeha, aʻo nā ʻiole i loko o ka hui inu Bpc 157 ua kūʻē loa i kēia pilikia kaʻa.
I ka hopena, aia ka waiwai nui o Bpc 157 i kāna mau ʻano hoʻoponopono endogenous a me nā ʻōnaehana multi-system, e hāʻawi ana i nā hoʻonā hou no ka ʻeha refractory, nā kīnā ʻole, a me nā maʻi neuropsychiatric. Ma ke kahua o ka ʻeha haʻuki, hiki iā ia ke hoʻolōʻihi i ka hoʻoponopono ʻana a me ka hoʻoponopono hou ʻana o nā ʻiʻo e like me nā ʻiʻo, nā tendons, a me nā ligaments, e hoʻopōkole i ka manawa hoʻihoʻi, a loaʻa ka hopena therapeutic maikaʻi i ka trauma acute. I ka mālamaʻana i nā kuni, hiki i ka Bpc 157 ke hoʻonui nui i nā hana olaola o nā pūnaewele endothelial e like me ka hoʻonuiʻana, ka neʻeʻana, a me ka hoʻokumuʻana i ka tubule, pēlā e hoʻonui ai i ka hoʻoponoponoʻana i nāʻeha wela. Eia kekahi, he hopena pale ia i ka'ōpū o ka'ōpū, hiki ke hoʻoikaika i ka ho'ōlaʻana i nā maʻi maʻi'ōpū, a pale a hoʻohaʻahaʻa i nā maʻi maʻi. Hōʻike pū ka Bpc 157 i ka hiki i ka neuroprotection, ka pale ʻana i ka ʻōnaehana nerve ma o nā ʻano hana e like me ka hoʻemi ʻana i ka pane inflammatory a me ka pale ʻana i ka apoptosis. Loaʻa iā ia kahi hopena pale i nā ʻōpū o ke kanaka e like me ka pancreas, ate, a me ka puʻuwai, e hōʻike ana i kāna ākea ākea o nā hopena biological e like me ka peptide multifunctional.
No ka mea kakau
ʻO nā mea i ʻōlelo ʻia ma luna nei ua noiʻi ʻia, hoʻoponopono ʻia a hōʻuluʻulu ʻia e Cocer Peptides.
Mea kākau moʻolelo ʻepekema
He haumana ʻo Predrag Sikiricis i hui pū ʻia me nā ʻoihana hoʻonaʻauao he nui, me ke Kulanui o Zagreb, University of Sarajevo, Sch Med, University of JJ Strossmayer Osijek, a me Rudjer Boskovic Institute. ʻO kāna noiʻi e pili ana i nā ʻano aʻoaʻo e like me Pharmacology & Pharmacy, Biochemistry & Molecular Biology, Gastroenterology & Hepatology, Physiology, a me Cell Biology.
Ua alakaʻi ka hui o Sikiric i ka noiʻi nui e pili ana i nā hopena cytoprotective o BPC157 i loko o nā ʻāpana like ʻole a me nā ʻiʻo, me kāna kuleana i ka hōʻeha neural a me nā ʻeha o ka ʻōpū. Loaʻa iā ia nā palapala hōʻailona no ka hoʻomohala ʻana i ka BPC, kahi lāʻau pharmacologically active, me kāna mau hana hoʻomākaukau a me nā noi therapeutic.
